CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Rocket Pharma - RCKT CFD

    23.33
    0.17%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.12
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Rocket Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 23.29
    Open* 22.7
    1-Year Change* 20.49%
    Day's Range* 22.69 - 23.34
    52 wk Range 14.89-24.65
    Average Volume (10 days) 765.71K
    Average Volume (3 months) 27.88M
    Market Cap 1.97B
    P/E Ratio -100.00K
    Shares Outstanding 90.16M
    Revenue N/A
    EPS -3.17
    Dividend (Yield %) N/A
    Beta 0.98
    Next Earnings Date Feb 26, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 23.33 0.25 1.08% 23.08 23.39 22.54
    Nov 30, 2023 23.29 0.06 0.26% 23.23 24.60 22.82
    Nov 29, 2023 22.81 0.34 1.51% 22.47 23.31 22.47
    Nov 28, 2023 22.37 0.27 1.22% 22.10 22.77 21.83
    Nov 27, 2023 22.73 0.76 3.46% 21.97 22.89 21.57
    Nov 24, 2023 22.17 0.55 2.54% 21.62 22.39 21.62
    Nov 22, 2023 21.86 0.04 0.18% 21.82 22.09 21.48
    Nov 21, 2023 21.83 -0.01 -0.05% 21.84 22.35 21.22
    Nov 20, 2023 21.96 0.04 0.18% 21.92 22.69 21.63
    Nov 17, 2023 21.91 0.54 2.53% 21.37 22.19 21.26
    Nov 16, 2023 21.32 0.07 0.33% 21.25 21.62 20.74
    Nov 15, 2023 21.80 -0.26 -1.18% 22.06 23.04 21.79
    Nov 14, 2023 22.06 1.56 7.61% 20.50 22.08 20.21
    Nov 13, 2023 19.48 1.26 6.92% 18.22 19.48 17.95
    Nov 10, 2023 18.51 0.36 1.98% 18.15 18.82 17.79
    Nov 9, 2023 18.15 -1.42 -7.26% 19.57 19.66 18.08
    Nov 8, 2023 19.54 -1.18 -5.69% 20.72 20.72 19.39
    Nov 7, 2023 20.43 0.46 2.30% 19.97 20.54 19.50
    Nov 6, 2023 19.91 -1.06 -5.05% 20.97 21.24 19.65
    Nov 3, 2023 20.95 1.63 8.44% 19.32 21.41 19.32

    Rocket Pharma Events

    Time (UTC) Country Event
    Monday, February 26, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Rocket Pharmaceuticals Inc Earnings Release
    Q4 2023 Rocket Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 224.343 167.248 134.303 76.151 71.156
    Selling/General/Admin. Expenses, Total 55.573 41.772 27.921 17.528 17.886
    Research & Development 165.57 125.476 106.382 58.623 53.27
    Operating Income -224.343 -167.248 -134.303 -76.151 -71.156
    Interest Income (Expense), Net Non-Operating 2.027 0.091 -4.817 -2.544 -4.349
    Other, Net 0.453 -1.912 -0.58 1.425 0.987
    Net Income Before Taxes -221.863 -169.069 -139.7 -77.27 -74.518
    Net Income After Taxes -221.863 -169.069 -139.7 -77.27 -74.518
    Net Income Before Extra. Items -221.863 -169.069 -139.7 -77.27 -74.518
    Net Income -221.863 -169.069 -139.7 -77.27 -74.518
    Income Available to Common Excl. Extra. Items -221.863 -169.069 -139.7 -77.27 -74.518
    Income Available to Common Incl. Extra. Items -221.863 -169.069 -139.7 -77.27 -74.518
    Diluted Net Income -221.863 -169.069 -139.7 -77.27 -74.518
    Diluted Weighted Average Shares 68.1489 63.2354 55.3807 49.0104 39.3777
    Diluted EPS Excluding Extraordinary Items -3.25556 -2.67364 -2.52254 -1.57661 -1.89239
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -3.20861 -2.67364 -2.52254 -1.57661 -1.89239
    Unusual Expense (Income) 3.2
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0
    Total Operating Expense 68.757 62.194 69.082 58.488 54.21
    Selling/General/Admin. Expenses, Total 17.374 15.823 17.145 13.805 12.854
    Research & Development 51.383 46.371 50.037 43.383 41.356
    Operating Income -68.757 -62.194 -69.082 -58.488 -54.21
    Interest Income (Expense), Net Non-Operating 0.378 1.44 0.778 0.888 0.204
    Other, Net 2.678 2.419 1.581 -0.156 -0.396
    Net Income Before Taxes -65.701 -58.335 -66.723 -57.756 -54.402
    Net Income After Taxes -65.701 -58.335 -66.723 -57.756 -54.402
    Net Income Before Extra. Items -65.701 -58.335 -66.723 -57.756 -54.402
    Net Income -65.701 -58.335 -66.723 -57.756 -54.402
    Income Available to Common Excl. Extra. Items -65.701 -58.335 -66.723 -57.756 -54.402
    Income Available to Common Incl. Extra. Items -65.701 -58.335 -66.723 -57.756 -54.402
    Diluted Net Income -65.701 -58.335 -66.723 -57.756 -54.402
    Diluted Weighted Average Shares 80.4724 79.4535 76.3752 66.2155 65.4765
    Diluted EPS Excluding Extraordinary Items -0.81644 -0.7342 -0.87362 -0.87224 -0.83086
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.81644 -0.7342 -0.84874 -0.85261 -0.83086
    Unusual Expense (Income) 1.9 1.3
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 364.06 392.059 487.345 307.754 209.088
    Cash and Short Term Investments 356.394 388.74 482.719 304.115 205.73
    Cash & Equivalents 140.517 232.694 297.098 185.383 111.355
    Short Term Investments 215.877 156.046 185.621 118.732 94.375
    Prepaid Expenses 7.666 3.319 4.626 3.639 3.358
    Total Assets 551.807 497.02 590.824 372.121 251.313
    Property/Plant/Equipment, Total - Net 77.645 72.348 70.641 31.572 2.027
    Property/Plant/Equipment, Total - Gross 86.738 77.571 72.687 32.251 2.506
    Accumulated Depreciation, Total -9.093 -5.223 -2.046 -0.905 -0.479
    Other Long Term Assets, Total 1.948 1.798 2.023 1.98 1.981
    Total Current Liabilities 39.169 22.167 32.617 18.309 15.372
    Accounts Payable
    Accrued Expenses 35.16 19.996 25.263 17.969 14.783
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.273 0.482 0.835 0.34 0.589
    Total Liabilities 62.121 42.296 87.305 64.824 57.276
    Total Long Term Debt 19.269 19.144 54.054 45.049 41.447
    Long Term Debt 0 35.066 45.049 41.447
    Other Liabilities, Total 3.683 0.985 0.634 1.466 0.457
    Total Equity 489.686 454.724 503.519 307.297 194.037
    Common Stock 0.791 0.645 0.61 0.548 0.452
    Additional Paid-In Capital 1203.07 946.152 825.794 489.925 300.253
    Retained Earnings (Accumulated Deficit) -713.775 -491.912 -322.843 -183.143 -105.873
    Other Equity, Total -0.357 -0.161 -0.042 0.02 -0.127
    Total Liabilities & Shareholders’ Equity 551.807 497.02 590.824 372.121 251.313
    Total Common Shares Outstanding 79.1207 64.5059 60.9964 54.769 45.1947
    Goodwill, Net 39.154 30.815 30.815 30.815 30.815
    Redeemable Preferred Stock 0 0 0 0 0
    Long Term Investments 43.276 0 7.402
    Treasury Stock - Common -0.047 0 -0.053 -0.668
    Current Port. of LT Debt/Capital Leases 1.736 1.689 6.519
    Capital Lease Obligations 19.269 19.144 18.988
    Intangibles, Net 25.724
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 446.865 312.074 338.033 364.06 311.131
    Cash and Short Term Investments 437.171 307.04 331.084 356.394 306.534
    Cash & Equivalents 225.657 45.076 64.579 140.517 196.669
    Short Term Investments 211.514 261.964 266.505 215.877 109.865
    Prepaid Expenses 9.694 5.034 6.949 7.666 4.597
    Total Assets 598.762 461.781 514.757 551.807 417.265
    Property/Plant/Equipment, Total - Net 85.679 82.925 81.09 77.645 73.51
    Property/Plant/Equipment, Total - Gross 98.321 94.347 91.319 86.738 81.512
    Accumulated Depreciation, Total -12.642 -11.422 -10.229 -9.093 -8.002
    Goodwill, Net 39.154 39.154 39.154 39.154 30.815
    Other Long Term Assets, Total 1.914 1.904 1.799 1.948 1.809
    Total Current Liabilities 33.476 34.346 31.206 39.169 30.181
    Accrued Expenses 29.85 31.471 27.788 35.16 26.577
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 1.773 1.76 1.748 1.736 1.724
    Other Current Liabilities, Total 1.853 1.115 1.67 2.273 1.88
    Total Liabilities 57.676 58.811 55.881 62.121 49.952
    Total Long Term Debt 19.341 19.319 19.294 19.269 19.242
    Long Term Debt
    Capital Lease Obligations 19.341 19.319 19.294 19.269 19.242
    Other Liabilities, Total 4.859 5.146 5.381 3.683 0.529
    Total Equity 541.086 402.97 458.876 489.686 367.313
    Common Stock 0.901 0.805 0.804 0.791 0.678
    Additional Paid-In Capital 1440.4 1240.74 1230.32 1203.07 1014.28
    Retained Earnings (Accumulated Deficit) -899.71 -837.811 -772.11 -713.775 -647.052
    Other Equity, Total -0.508 -0.722 -0.09 -0.357 -0.596
    Total Liabilities & Shareholders’ Equity 598.762 461.781 514.757 551.807 417.265
    Total Common Shares Outstanding 90.1466 80.5188 80.4096 79.1207 67.8388
    Redeemable Preferred Stock 0 0 0 0 0
    Intangibles, Net 25.15 25.724 25.724 25.724
    Long Term Investments 0 0 28.957 43.276
    Treasury Stock - Common -0.047 -0.047 -0.047
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -221.863 -169.069 -139.7 -77.27 -74.518
    Cash From Operating Activities -178.142 -121.163 -74.64 -64.663 -53.788
    Cash From Operating Activities 6.266 5.373 1.145 0.426 0.33
    Non-Cash Items 31.379 45.919 48.886 15.907 16.015
    Cash Taxes Paid 0 0 0.026 0.002
    Cash Interest Paid 0 0.148 2.96 2.99 4.485
    Changes in Working Capital 6.076 -3.386 15.029 -3.726 4.385
    Cash From Investing Activities -69.326 18.853 -96.591 -39.011 -5.272
    Capital Expenditures -8.619 -7.715 -29.059 -23.269 -1.453
    Other Investing Cash Flow Items, Total -60.707 26.568 -67.532 -15.742 -3.819
    Cash From Financing Activities 155.288 37.681 282.989 177.791 153.502
    Issuance (Retirement) of Stock, Net 155.288 37.681 283.84 178.135 153.502
    Issuance (Retirement) of Debt, Net 0 0
    Net Change in Cash -92.18 -64.629 111.758 74.117 94.442
    Financing Cash Flow Items 0 0 -0.851 -0.344
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -58.335 -221.863 -155.14 -97.384 -42.982
    Cash From Operating Activities -57.56 -178.142 -122.121 -78.262 -39.223
    Cash From Operating Activities 1.673 6.266 4.488 2.868 1.302
    Non-Cash Items 6.572 31.379 22.625 14.793 6.887
    Cash Interest Paid 0 0 0 0
    Changes in Working Capital -7.47 6.076 5.906 1.461 -4.43
    Cash From Investing Activities -36.721 -69.326 39.259 15.794 -62.995
    Capital Expenditures -3.022 -8.619 -5.355 -4.852 -1.955
    Other Investing Cash Flow Items, Total -33.699 -60.707 44.614 20.646 -61.04
    Cash From Financing Activities 18.343 155.288 46.848 17.322 0.076
    Issuance (Retirement) of Stock, Net 18.343 155.288 46.848 17.322 0.076
    Issuance (Retirement) of Debt, Net
    Net Change in Cash -75.938 -92.18 -36.014 -45.146 -102.142
    Financing Cash Flow Items 0
    Cash Taxes Paid
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    RTW Investments L.P. Investment Advisor/Hedge Fund 20.1813 18157605 469833 2023-09-15 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 5.7156 5142457 1034529 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.1013 4589794 67504 2023-06-30 LOW
    Maverick Capital, Ltd. Hedge Fund 4.8681 4379970 -27653 2023-06-30 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.4951 4044300 -212806 2023-06-30 LOW
    Westfield Capital Management Company, L.P. Investment Advisor/Hedge Fund 4.0632 3655787 419879 2023-06-30 MED
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.5328 3178524 -841162 2023-06-30 LOW
    Citadel Advisors LLC Hedge Fund 2.8766 2588108 -70841 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 2.2718 2043968 245450 2023-06-30 LOW
    Boxer Capital, L.L.C. Hedge Fund 1.6294 1466051 0 2023-06-30 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.4884 1339159 66665 2023-06-30 LOW
    Makker (Gotham) Individual Investor 1.4799 1331486 0 2023-04-24 LOW
    Avidity Partners Management LP Hedge Fund 1.4738 1326000 81600 2023-06-30 HIGH
    Lord, Abbett & Co. LLC Investment Advisor 1.3306 1197182 41844 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3161 1184103 28364 2023-06-30 LOW
    Perceptive Advisors LLC Private Equity 1.2986 1168363 300631 2023-06-30 MED
    Cowen & Co., LLC Research Firm 1.2226 1100000 0 2023-06-30 MED
    Goldman Sachs & Company, Inc. Research Firm 1.1182 1006026 -492147 2023-06-30 MED
    Shah (Gaurav D) Individual Investor 1.0349 931092 3212 2023-08-17 LOW
    Novo Holdings A/S Venture Capital 1.0225 920000 0 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Rocket Pharma Company profile

    About Rocket Pharmaceuticals Inc

    Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company that is focused on the development of gene therapies for rare and devastating diseases. The Company’s clinical-stage ex vivo lentiviral vector (LVV) programs include: Fanconi Anemia (FA), is a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; Leukocyte Adhesion Deficiency-I (LAD-I), is a genetic disorder that causes the immune system to malfunction; Pyruvate Kinase Deficiency (PKD), is a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia, and Infantile Malignant Osteopetrosis (IMO), is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Rocket Pharmaceuticals Inc revenues was not reported. Net loss increased 21% to $169.1M. Higher net loss reflects research and development expense balanci increase of 15% to $113.5M (expense), General and administrative - Balancing increase of 47% to $24.5M (expense), Stock-based Compensation in SGA increase of 54% to $17.3M (expense).

    Industry: Bio Therapeutic Drugs

    350 5th Ave Ste 7530
    NEW YORK
    NEW YORK 10118-7501
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    XRP/USD

    0.63 Price
    +0.780% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    BTC/USD

    39,679.05 Price
    +0.070% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading